ASK1 ‐Induced FGF21 Synthesis in the Liver Prevents Obesity in Mice
Obesity · 2026-08 · 34 (8) · 1635-1646
DOI: 10.1002/oby.70261 ↗At a glance
Journal article in Obesity, published online on 2026-07-16. Written by Anne Goergen and 8 co-authors. Institution: Division of Pediatric Endocrinology and Diabetology, University of Zurich, Zurich, Switzerland. Major MEDLINE topics: Fibroblast Growth Factors, Liver, MAP Kinase Kinase Kinase 5, Obesity. 52 references. The full text is freely available (open access, CC BY 4.0). Funded by: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Uniscientia Foundation.
Abstract (original language)
Objective
Fibroblast growth factor 21 (FGF21) is a stress‐induced hormone secreted by the liver. It has a beneficial role in the regulation of glucose and energy metabolism. Herein, we identify apoptosis signal regulating kinase 1 (ASK1) as an inducer of hepatic FGF21 synthesis.
Methods
Glucose and energy metabolism were assessed in liver‐specific ASK1 overexpressing (ASK1 +hep ) and control littermate (ASK1 f/f ) mice fed a regular chow or high fat diet (HFD) for 20 weeks. Liver and fat depots were analyzed using RNA sequencing. Hepatic Fgf21 expression was downregulated using adeno‐associated virus (AAV) expressing short‐hairpin RNA sequences. ASK1 and FGF21 expression was determined in human liver samples.
Results
HFD‐fed ASK1 +hep mice exhibited improved glucose metabolism, elevated energy expenditure, and reduced body weight. FGF21 plasma levels were increased in HFD‐fed ASK1 +hep mice, and its reduction in vivo blunted beneficial effects on obesity. Mechanistically, ASK1 promoted hepatic Fgf21 gene expression via the transcription factor ATF4. In humans, hepatic ASK1 expression correlated positively with FGF21 and negatively with BMI and visceral fat area.
Conclusions
We describe a novel role of hepatic ASK1 in the synthesis of FGF21. Hence, increasing hepatic ASK1 expression might be a novel strategy to combat obesity‐associated metabolic complications.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Pediatric Endocrinology and Diabetology, University of Zurich, Zurich, Switzerland.
- Children's Research Center, University Children's Hospital, University of Zurich, Zurich, Switzerland.
- Rosen Lab, Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland.
- Medical Department III - Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany.
- Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany.
ORCID profiles: Stephan Wueest, Daniel Konrad
Funding
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Uniscientia Foundation
Cite
APA
Goergen, A., Challa, T. D., Villaroel-Vicente, C., Borsigova, M., van Krieken, P. P., Wolfrum, C., Blüher, M., Wueest, S., & Konrad, D. (2026). ASK1 ‐Induced FGF21 Synthesis in the Liver Prevents Obesity in Mice. Obesity, 34(8), 1635-1646. https://doi.org/10.1002/oby.70261
Vancouver
Goergen A, Challa TD, Villaroel-Vicente C, Borsigova M, van Krieken PP, Wolfrum C, et al. ASK1 ‐Induced FGF21 Synthesis in the Liver Prevents Obesity in Mice. Obesity. 2026;34(8):1635-1646. doi:10.1002/oby.70261
BibTeX
@article{Goergen2026,
author = {Goergen, Anne and Challa, Tenagne D and Villaroel-Vicente, Carlos and Borsigova, Marcela and van Krieken, Pim P and Wolfrum, Christian and Blüher, Matthias and Wueest, Stephan and Konrad, Daniel},
title = {ASK1 ‐Induced FGF21 Synthesis in the Liver Prevents Obesity in Mice},
journal = {Obesity},
year = {2026},
volume = {34},
number = {8},
pages = {1635--1646},
doi = {10.1002/oby.70261}
}
EUVIMED